Koh Furuta

 

Furuta2

Koh Furuta

kfuruta@kcch.jp

Title of Presentation

“Status quo and the future; Biobankings in Japan”

 

Date and Place

Session A5

 

Speaker Biography

Hospital

Kanagawa Cancer Center Hospital

Division of Clinical Laboratories

Yokohama, Japan

Education and Training

Kyushu University School of Medicine, Fukuoka, Japan

Residency in Surgery

Residency in Anesthesiology

Medical Activities

Japanese Society of Laboratory Medicine(JSLM)

Japanese Society for Clinical Microbiology

The Japan Society for Clinical Laboratory Automation

American Society for Investigative Pathology (ASIP)

International Society for Biological and Environmental Repositories (ISBER)

American Association for Cancer Research (AACR)

Society for Cryobiology

Research Experiences

Research in Pathology

Niigata University, Niigata, Japan

Johns Hopkins University, Baltimore, U.S.A.

Research in Surgery

Johns Hopkins University, Baltimore, U.S.A.

Research in Clinical Chemistry and Laboratory Medicine

Kyushu University, Fukuoka, Japan

University of Occupational and Environmental Health, Kitakyushu, Japan

National Cancer Center Hospital, Tokyo, Japan.

Additional Experiences

Sabbatical

Department of Mechanical Engineering at the University of Minnesota.

Social Activity

ISO/TC276 Expert (WG2; Biobanking and Resources)

Award

ISBER Special Service Award, 2015

 

Abstract

Biobanks in Japan are mostly small and diversified based on individual research activities in the academic sector. At least 41 facilities are listed as a biobank. Most of the funding is public, including government sponsored grants of various types. Among these listed biobanks, three major biobanks (Tohoku Medical Megabank Project, Biobank Japan, National Center Biobank Network) are supported by government. In the 2016 fiscal year budget, these three biobanks acquired around €45 M. The funding covers basic expenses of biobanking and its associated studies including cohort studies and genome analysis. Providing samples to outside third parties, especially to industry, had not been active in the past. Recently however, many funding bodies have encouraged biobanks to provide samples to the outside parties, especially to industry. More than ever the quality of samples but also the quality of management systems came under focus. Sixty three clinical laboratories are accredited to ISO15189 at present;10 umbrella organizations of these facilities established biobanks in various contexts. This number is constantly increasing. Some biobanks or bio-resource facilities also have acquired ISO 9001. Awareness and need for biobanking standards pushed biobanks and respectively their stakeholders like academia, industry and government into transition to implement applicable standards. This has resulted in participation in the current discussions and activities of ISO/TC 276 / WG2 and contributing in this way to the new era of standardization. We have prepared and are ready to harmonize our efforts and feel confident to build up new partnerships in biobanking around the world.